Pershing Square Announces New Position in Valeant Pharmaceuticals International

AMSTERDAM--(BUSINESS WIRE)-- Regulatory News:

Pershing Square Holdings, Ltd. (ticker: PSH:NA) announced today a new position in Valeant Pharmaceuticals International, Inc. (ticker: NYSE: VRX) representing approximately 16.9% of the PSH portfolio (based on the closing NAV of PSH and the closing share price of VRX on Friday, 6 March 2015).

Pershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd., announced that various funds it manages have purchased 16,473,933 shares of Valeant Pharmaceuticals International, Inc., representing 4.9% of Valeant.

About Pershing Square Holdings, Ltd.

Pershing Square Holdings, Ltd. is a concentrated, research‐intensive, fundamental value investor in the public markets.

MEDIA CONTACTS
StockWell Communications
Tim Burt, +44 (0)20 7240 2486
[email protected]

Source: Pershing Square Holdings, Ltd.

You May Also Be Interested In

• Lithia & Driveway (LAD) Reports Record First Quarter Revenue of $8.6 billion, 23% Increase
• Of Consumers, 70% Are Excited about GenAI in the Workplace, but Only 43% Are Enthusiastic about Its Impact on Daily Life
• Festi hf.: Presentation of Q1 2024 results